{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:54:51Z","timestamp":1793336091934,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"DOI":"10.1007\/s00213-026-07016-9","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T03:34:15Z","timestamp":1770003255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of intranasal esketamine in the treatment of patients with treatment-resistant depression: an observational study based on data collected in a Spravato treatment program at the Institute of Living, Hartford, CT"],"prefix":"10.1007","author":[{"given":"Benjamin","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Winokur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"2","key":"7016_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4088\/JCP.17m11725","volume":"79","author":"TB Amos","year":"2018","unstructured":"Amos TB, Tandon N, Lefebvre P et al (2018) Direct and indirect cost burden and change of employment status in treatment-resistant depression: A matched-cohort study using a US commercial claims base. J Clin Psychiatry 79(2):24\u201333","journal-title":"J Clin Psychiatry"},{"key":"7016_CR2","volume-title":"Advances in neuropsychiatry and psychopharmacology: volume 2 refractory depression","author":"J Amsterdam","year":"1991","unstructured":"Amsterdam J (1991) Advances in neuropsychiatry and psychopharmacology: volume 2 refractory depression. Raven, NY"},{"key":"7016_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/15622975.2019.1635270","volume":"20","author":"L Bartova","year":"2019","unstructured":"Bartova L, Dold M, Kautzky A et al (2019) Results of the European group for the study of resistant depression (GSRD) \u2013 basis for further research and clinical practice. World J Biol Psychiatry 20:427\u2013448","journal-title":"World J Biol Psychiatry"},{"issue":"4","key":"7016_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A et al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47(4):351\u2013354","journal-title":"Biol Psychiatry"},{"key":"7016_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jad.2023.12.038","volume":"348","author":"G D\u2019Andrea","year":"2024","unstructured":"D\u2019Andrea G, Pettorruso M, Di Lorenzo G et al (2024) The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: a post-hoc analysis of pooled real-world data. J Affect Disord 348:314\u2013322","journal-title":"J Affect Disord"},{"issue":"9","key":"7016_CR5","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"E Daley","year":"2019","unstructured":"Daley E, Trivedi M, Janik A et al (2019) Efficacy of Esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 76(9):893\u2013903","journal-title":"JAMA Psychiatry"},{"key":"7016_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jad.2023.09.030","volume":"342","author":"I Estrade","year":"2023","unstructured":"Estrade I, Petit A, Sylvestre V et al (2023) Early effects predict trajectories of response to Esketamine in treatment-resistant depression. J Affect Disord 342:166\u2013176","journal-title":"J Affect Disord"},{"key":"7016_CR8","unstructured":"European Medicines Agency (2025) Clinical investigation of medicinal products in the treatment of depression \u2013 Scientific guideline. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf"},{"key":"7016_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","volume":"53","author":"M Fava","year":"2003","unstructured":"Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53:649\u2013659","journal-title":"Biol Psychiatry"},{"key":"7016_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12888-018-1679-x","volume":"18","author":"A Fekadu","year":"2018","unstructured":"Fekadu A, Donocik JG, Cleare AJ (2018) Standardization framework for the Maudsley staging method for treatment resistance in depression. BMC Psychiatry 18:100","journal-title":"BMC Psychiatry"},{"issue":"1","key":"7016_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3111\/13696998.2012.724745","volume":"16","author":"RL Feldman","year":"2013","unstructured":"Feldman RL, Dunner DL, Muller JS et al (2013) Medicare patient experience with vagus nerve stimulation for treatment-resistant depression. J Med Econ 16(1):62\u201374","journal-title":"J Med Econ"},{"key":"7016_CR28","unstructured":"U.S. Food and Drug Administration. Major depressive disorder: developing drugs for treatment. Center for Drug Evaluation and Research. June (2018).\u00a0https:\/\/www.fda.gov\/media\/113988\/download"},{"key":"7016_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1176\/appi.ajp.20240515","volume":"182","author":"K Fountoulakis","year":"2025","unstructured":"Fountoulakis K, Saitis A, Schatzberg A (2025) Esketamine treatment for depression in adults: a PRISMA systematic review and meta-analysis. Am J Psychiatry 182:259\u2013275","journal-title":"Am J Psychiatry"},{"issue":"8","key":"7016_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/brb3.3171","volume":"13","author":"D Kern","year":"2023","unstructured":"Kern D, Canuso C, Daly E et al (2023) Suicide specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone. Brain Behav 13(8):1\u201311","journal-title":"Brain Behav"},{"key":"7016_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","volume":"319","author":"G Martinotti","year":"2022","unstructured":"Martinotti G, Vita A, Fagiolini A et al (2022) Real world experience of Esketamien use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study). J Affect Disord 319:646\u2013654","journal-title":"J Affect Disord"},{"key":"7016_CR15","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","volume":"22","author":"R McIntyre","year":"2023","unstructured":"McIntyre R, Alswuwaidan M, Baune B et al (2023) Treatment resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry 22:394\u2013412","journal-title":"World Psychiatry"},{"issue":"10","key":"7016_CR16","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","volume":"170","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Iosifescu DV, Chang LC et al (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170(10):1134\u20131142","journal-title":"Am J Psychiatry"},{"issue":"4","key":"7016_CR17","first-page":"429","volume":"26","author":"AA Nierenberg","year":"1990","unstructured":"Nierenberg AA, White K (1990) What next? A review of Pharmacological strategies for treatment resistant depression. Psychopharmacol Bull 26(4):429\u2013460","journal-title":"Psychopharmacol Bull"},{"key":"7016_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jval.2015.09.2938","volume":"19","author":"C Nordon","year":"2016","unstructured":"Nordon C, Karcher K, Groenwold RHH et al (2016) The efficacy-effectiveness gap: historical background and current conceptualization. Value Health 19:75\u201381","journal-title":"Value Health"},{"key":"7016_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jad.2016.08.019","volume":"205","author":"FPML Peeters","year":"2016","unstructured":"Peeters FPML, Ruhe HG, Wichers M et al (2016) The Dutch measure for quantification of treatment resistance in depression (DM-TRD): an extension of the Maudsley staging method. J Affect Disord 205:365\u2013371","journal-title":"J Affect Disord"},{"issue":"6","key":"7016_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","volume":"176","author":"V Popova","year":"2019","unstructured":"Popova V, Daly E, Trivedi M et al (2019) Efficacy and safety of flexibly dosed Esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double blind active-controlled study. Am J Psychiatry 176(6):428\u2013438","journal-title":"Am J Psychiatry"},{"key":"7016_CR20","first-page":"47","volume":"6","author":"F Porsolt","year":"2025","unstructured":"Porsolt F, Galito-Rocha N, Toledo-Arruda AC et al (2025) Efficacy and effectiveness trials have different goals, use different tools, and generate different messages. Pragmat Obs Res 6:47\u201354","journal-title":"Pragmat Obs Res"},{"key":"7016_CR22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2165\/00019053-199915050-00001","volume":"15","author":"DA Revicki","year":"1999","unstructured":"Revicki DA, Frank L (1999) Pharmacoeconomic evaluation in the real world. Effectiveness vs efficacy studies. PharmacoEconomics 15:423\u2013434","journal-title":"PharmacoEconomics"},{"issue":"11","key":"7016_CR23","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR et al (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 163(11):1905\u20131917","journal-title":"Am J Psychiatry"},{"key":"7016_CR24","first-page":"352","volume":"26","author":"L Samalin","year":"2022","unstructured":"Samalin L, Rotharmel M, Mekaoui L et al (2022) Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early access programme. J Psychiatr Pract 26:352\u2013362","journal-title":"J Psychiatr Pract"},{"key":"7016_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/7262794","author":"L Samalin","year":"2024","unstructured":"Samalin L, Mekaoui L, Rotharmel M et al (2024) Use of Esketamine nasal spray in patients with treatment-resistant depression in routine practice: a real world French study. Depress Anxiety. https:\/\/doi.org\/10.1155\/2024\/7262794","journal-title":"Depress Anxiety"},{"issue":"16","key":"7016_CR26","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2023.4855","volume":"329","author":"RC Sheldrick","year":"2023","unstructured":"Sheldrick RC (2023) Randomized trials vs Real-World evidence: how can both inform Decision-making? JAMA 329(16):1353\u20131353","journal-title":"JAMA"},{"issue":"Suppl 13","key":"7016_CR27","first-page":"23","volume":"58","author":"ME Thase","year":"1997","unstructured":"Thase ME, Rush AJ (1997) When at first you don\u2019t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58(Suppl 13):23\u201329","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"7016_CR29","doi-asserted-by":"publisher","first-page":"446","DOI":"10.4088\/JCP.08com04901","volume":"70","author":"AP Weiss","year":"2009","unstructured":"Weiss AP, Guidi J, Fava M (2009) Closing the efficacy-effectiveness gap: translating both the what and the how from randomized controlled trials to clinical practice. J Clin Psychiatry 70(4):446\u2013449","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"7016_CR30","doi-asserted-by":"publisher","first-page":"21m14318","DOI":"10.4088\/JCP.21m14318","volume":"83","author":"D Williamson","year":"2022","unstructured":"Williamson D, Godate J, Kern Sliwa J et al (2022) Longitudinal course of adverse events with Esketamine nasal spray: a post hoc analysis of pooled data from phase 3 trials in patients with treatment-resistant depression. J Clin Psychiatry 83(6):21m14318","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"7016_CR31","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Carlson PJ et al (2006) A randomized trial of an N-methyl-D- aspartate antagonist in treatment-resistant depression. Arch Gen Psychiatry 63(8):856\u2013864","journal-title":"Arch Gen Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07016-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-026-07016-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07016-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T03:34:37Z","timestamp":1770003277000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-026-07016-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":31,"alternative-id":["7016"],"URL":"https:\/\/doi.org\/10.1007\/s00213-026-07016-9","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"Project approved by Hartford Healthcare Institutional Review Board and the University of Connecticut School of Medicine Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}